Zymeworks Inc. ZYME
Set alert
At close · Oct 30
After hours · Oct 30, 4:48 PM ET
- YTD
- +8.66%
- 1 year
- +49.63%
- Open
- 28.81
- Prev close
- 28.71
- Mkt cap
- 2.06B
- Vol
- 2.88M
- Avg vol
- 917.16K
- EPS
- -2.02
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 28.26
- High
- 29.02
- Forward P/E
- 23.55
- Beta
- 1.17
- Short ratio
- 5.07
- Inst. own
- 100.21%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 27.26
- 200-d avg
- 25.20
- 1y target
- 41.50
5D chart
Events in this range
- Oct 28, 2026Rating: Truist Securities · Buy → Buy
Signals (117)
| Name | Time | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:00 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 12:45 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:40 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 12:20 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:10 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 11:40 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:35 AM | 1 day ago |
| SMA: Bearish | Oct 30, 11:30 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:40 AM | 1 day ago |
| MACD: Buy Signal | Oct 30, 10:40 AM | 1 day ago |
| SMA: Bullish | Oct 30, 10:35 AM | 1 day ago |
| MACD: Sell Signal | Oct 30, 9:55 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:50 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:50 AM | 1 day ago |
| SMA: Bullish | Oct 30, 9:45 AM | 1 day ago |
| SMA: Bearish | Oct 30, 9:40 AM | 1 day ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:10 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:05 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:45 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 11:35 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bearish | Oct 29, 11:00 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:45 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:25 AM | 2 days ago |
| MACD: Sell Signal | Oct 29, 10:20 AM | 2 days ago |
| SMA: Bullish | Oct 29, 10:15 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:10 AM | 2 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 2 days ago |
| RSI: Overbought | Oct 29, 9:40 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 2 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:40 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:40 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 1:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 3 days ago |
| SMA: Bearish | Oct 28, 11:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 28, 10:55 AM | 3 days ago |
| RSI: Overbought | Oct 28, 10:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 9:50 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 27, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 2:30 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 1:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 1:35 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 11:55 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 10:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:25 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 27, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:50 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 4 days ago |
| RSI: Overbought | Oct 26, 3:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 11:55 AM | 5 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 26, 11:10 AM | 5 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 26, 10:20 AM | 5 days ago |
News
2 days ago zacks.com
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
Zymeworks (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
3 days ago benzinga.com
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $35
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $34 to $35.
4 days ago marketbeat.com
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its…
4 days ago seekingalpha.com
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
4 days ago businesswire.com
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today…
1 week ago globenewswire.com
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
-
1 week ago benzinga.com
Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M
Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’sZymeworks will conduct the Phase 1a monotherapy…
1 week ago globenewswire.com
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
1 week ago globenewswire.com
Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
2 weeks ago globenewswire.com
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
-
3 weeks ago benzinga.com
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $34.
4 weeks ago marketbeat.com
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook
Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax…
-
1 month ago benzinga.com
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $38 to $39.
1 month ago seekingalpha.com
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (ZYME) M&A Call Transcript
1 month ago benzinga.com
Zymeworks Updates Annual Financial Targets After Finalizing Theravance Biopharma Deal
Zymeworks completes its Theravance Biopharma acquisition, boosts 2026 revenue guidance, and gains recurring revenue from YUPELRI sales.
-
1 month ago benzinga.com
Zymeworks Sees FY2026 Sales $278.000M-$292.000M vs $302.577M Est
Zymeworks (NASDAQ:ZYME) sees FY2026 sales of $278.000 million-$292.000 million vs $302.577 million analyst estimate.
-
1 month ago benzinga.com
Zymeworks Guides FY26 Total Sales, Including Collaboration Revenue From YUPELRI, Of $278M-$292M And Adjusted EBITDA Of $114M-$128M
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…
1 month ago globenewswire.com
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
1 month ago defenseworld.net
Bank of America Corp DE Buys 219,071 Shares of Zymeworks Inc. $ZYME
Bank of America Corp DE purchased a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
1 month ago globenewswire.com
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse…
1 month ago seekingalpha.com
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
Jupiter Topco LLC Buys New Position in Zymeworks Inc. $ZYME
Jupiter Topco LLC bought a new position in shares of Zymeworks Inc. (NASDAQ: ZYME) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange…
-
1 month ago benzinga.com
JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.
2 months ago seekingalpha.com
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab's FDA approval. Zanidatamab's first-line HER2+ gastroesophageal…
2 months ago defenseworld.net
Bank of America Corp DE Raises Position in Zymeworks Inc. $ZYME
Bank of America Corp DE lifted its stake in Zymeworks Inc. (NASDAQ: ZYME) by 164.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and…
2 months ago zacks.com
JAZZ Secures FDA Nod for Expanded Use of Ziihera in Gastric Cancer
Jazz Pharmaceuticals' Ziihera wins FDA approval for first-line HER2-positive GEA, expanding its market and showing strong progression-free and survival benefits.
-
2 months ago benzinga.com
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $37 to $38.
2 months ago benzinga.com
Abercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and…
2 months ago benzinga.com
MongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut…
-
2 months ago benzinga.com
Citizens Reiterates Market Outperform on Zymeworks, Maintains $32 Price Target
Citizens analyst Reni J. Benjamin reiterates Zymeworks (NASDAQ:ZYME) with a Market Outperform and maintains $32 price target.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $55
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $51 to $55.
2 months ago benzinga.com
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
FDA approves Jazz Pharmaceuticals' Ziihera combinations for first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
-
2 months ago benzinga.com
Jazz Pharmaceuticals' Two Ziihera-Containing Regimens Receives FDA Approval To Treat Adults With Unresectable Locally Advanced Or Metastatic Her2-Positive Gastroesophageal Adenocarcinoma
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of…
2 months ago defenseworld.net
Deutsche Bank AG Buys Shares of 397,190 Zymeworks Inc. $ZYME
Deutsche Bank AG purchased a new stake in Zymeworks Inc. (NASDAQ: ZYME) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission…
2 months ago zacks.com
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
-
2 months ago benzinga.com
B. Riley Securities Reiterates Buy on Zymeworks, Raises Price Target to $44
B. Riley Securities analyst Mayank Mamtani reiterates Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $40 to $44.
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $40
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $37 to $40.
-
2 months ago benzinga.com
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $32
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $31 to $32.
-
2 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $51
HC Wainwright & Co. analyst Robert Burns maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $46 to $51.
-
3 months ago benzinga.com
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $31
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $28 to $31.
-
4 months ago benzinga.com
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $37
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $34 to $37.
4 months ago benzinga.com
Zymeworks Targets Long-Term Cash Generation Through Theravance Acquisition
Zymeworks will acquire Theravance Biopharma for $929 million, adding YUPELRI cash flows and expanding its portfolio.
-
4 months ago benzinga.com
Theravance Biopharma Discloses Termination Fee Of $32.5M After Acquisition Offer By Zymeworks
The Merger Agreement contains certain customary termination rights for the Company and Parent. Subject to the terms and conditions of the Merger Agreement, the Company or Parent may terminate the…
-
4 months ago benzinga.com
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
Acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition of…
-
4 months ago benzinga.com
Reported Sunday, Zymeworks Presents Phase 1 Data For ZW191 ADC Showing 78.6% cORR In FRα-Positive And 47.4% In FRα-Negative Platinum-Resistant Ovarian Cancer Patients At ESMO 2026
ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression levelConfirmed objective response rate (cORR) of 78.6% in FRα-positive…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and maintains $46 price target.
-
5 months ago benzinga.com
Zymeworks Announces $125M Buyback Plan
Zymeworks Inc. (NASDAQ:ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced…
-
5 months ago benzinga.com
Wells Fargo Maintains Overweight on Zymeworks, Raises Price Target to $34
Wells Fargo analyst Eva Fortea Verdejo maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $33 to $34.
-
5 months ago benzinga.com
Zymeworks Q1 EPS $(0.59) Down From $(0.30) YoY, Sales $2.408M Down From $27.110M YoY
Zymeworks (NASDAQ:ZYME) reported quarterly losses of $(0.59) per share. This is a 96.67 percent decrease over losses of $(0.30) per share from the same period last year. The company reported $2.408…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Zymeworks, Maintains $46 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Zymeworks (NASDAQ:ZYME) with a Buy and maintains $46 price target.